logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Seeks Addl Information To Complete Review Of HyQ BLA - Quick Facts

Baxter International Inc. (BAX) and Halozyme Therapeutics Inc. (HALO) announced that the U.S. Food and Drug Administration is requesting additional information to complete its review of the HyQ Biologics License Application or BLA.

Baxter and Halozyme said that they will work closely together to develop studies to provide additional data to address concerns raised by the FDA related to the long-term chronic use of HyQ. The companies now expect to participate in a meeting of the FDA's Blood Products Advisory Committee concerning the agency's request for additional data.

The companies expect these requests to require additional time to complete and to delay the companies' anticipated regulatory review and approval timeline.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Treasury Secretary Steven Mnuchin's comments about the Lego Batman movie that he produced has raised questions from ethical groups whether he violated federal ethics rules that prohibit the promotion of products. Mnuchin, a former Hollywood producer, was asked several questions related to movies at an Axios event in Washington on Friday. A United Airlines gate agent barred two teenage girls from boarding a flight on Sunday for wearing leggings, noting that they failed to meet a dress code for special pass travelers. United spokesman Jonathan Guerin responded that the two girls traveling with a companion would not have been turned away for wearing leggings if they were paying customers. Alteryx, Inc., a provider of self-service data analytics software, is the latest tech company to go public in March. Alteryx said it has priced its IPO of 9 million shares of its Class A common stock at $14 per share, at the top end of its range of $12 to $14 per share.
comments powered by Disqus
Follow RTT